C difficile risk
Oral Bioavailability


500 mg IV q6h OR 1 g IV q8h

Meningitis: 2 g IV q8h

Infuse over 30 minutes

PNA < 14 DaysPNA ≥14 Days20 mg/kg/dose IV Q12H20 mg/kg/dose IV Q8H

PNA <14 DaysPNA ≥14 Days20 mg/kg/dose IV Q8H30 mg/kg/dose IV Q8H

The recommended dose is 40 mg/kg/dose


20 mg/mL

  1. Reconstitute 1 gram vial with 20mL of NS = 50 mg/mL
  2. Mix 4mL of 50 mg/mL concentration with 6mL of NS in a 10mL empty sterile vial = 20 mg/mL

50 mg/mL = 24H (after first use) 20 mg/mL = 24H Refrigerate

0 - 10 eGFR10 - 25 eGFR25 - 50 eGFR50+ eGFR500 - 1000 mg IV q24h500 - 1000 mg IV q12h500 - 1000 mg IV q8hNo dose adjustment required.

0 - 10 eGFR10 - 50 eGFR50+2 g IV Q24H2 g IV Q12HNo dosage adjustment required.

Increase dosing interval in renal impairment

General Information

Therapy of serious infections involving multi-drug resistant gram negative organisms.

Pregnancy: Limited published data in human pregnancies, however, due to the known safety of other beta lactams, meropenem is considered compatible in pregnancy.

Breastfeeding: Meropenem transfers into breastmilk in very small amounts and is not well absorbed orally. Two case reports published did not show any adverse events in two infants exposed to meropenem via breastmilk. Meropenem is given in therapeutic doses to infants. It is considered compatible with breastfeeding. Monitor the infant for any signs of gastrointestinal intolerance.

  • Scr

  • Liver enzymes

  • CBC if therapy prolonged

  • Immediate and delayed-type allergy

  • GI disturbance, cytopenias, positive Coombs

  • Liver enzyme abnormalities

Valproic acid - carbapenems decrease valproate levels and may decrease seizure threshold

Antimicrobial class: Carbapenem

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.